Prime Vector Technologies GmbH (PVT) was founded in 2019 as a Spin-Off from the Department of Immunology at the University of Tuebingen. Based on a viral vector platform technology, PVT develops innovative next generation vaccines that can be designed and developed using a modulatory brick system. The advantages of the platform include the very short development time, the ability to express multiple antigens and immunemodulators simultanously, as well as the excellent effectiveness of new vaccines. The versatility of this vaccine platform enables the development of prophylactic and therapeutic vaccines for both humans and animals, and is thus ideally suited to meet the requirements of efficient vaccines. In addition, individualized vaccines can be developed quickly and inexpensively. The PVT adresses rapidly growing markets with global volumes of currently US$54 billion. The technology is protected comprehensively by patent applications.